Compare SNOW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOW | SNY |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.2B | 104.5B |
| IPO Year | 2020 | 2001 |
| Metric | SNOW | SNY |
|---|---|---|
| Price | $329.24 | $43.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 43 | 5 |
| Target Price | ★ $248.62 | $58.00 |
| AVG Volume (30 Days) | ★ 4.6M | 3.3M |
| Earning Date | 05-20-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,683,946,000.00 | N/A |
| Revenue This Year | $28.57 | $3.49 |
| Revenue Next Year | $23.41 | $6.10 |
| P/E Ratio | ★ N/A | $6.14 |
| Revenue Growth | ★ 29.16 | N/A |
| 52 Week Low | $118.30 | $40.89 |
| 52 Week High | $341.95 | $52.68 |
| Indicator | SNOW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 71.19 | 50.80 |
| Support Level | $211.88 | $43.32 |
| Resistance Level | N/A | $45.22 |
| Average True Range (ATR) | 14.39 | 0.66 |
| MACD | 1.70 | 0.02 |
| Stochastic Oscillator | 84.79 | 50.88 |
Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflake's cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The company's data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.